Cécile Teuma1,2, Marie Perier-Muzet3,4, Solenne Pelletier5,6, Mathilde Nouvier5,6, Mona Amini-Adl3,4, Frédérique Dijoud5, Gérard Duru3,4, Luc Thomas3,4, Denis Fouque5,6, Maurice Laville5,6, Stéphane Dalle3,4. 1. Department of Nephrology, Centre Hospitalier Lyon Sud, 165, Chemin du Grand Revoyet, 69495, Pierre Bénite, France. cecile.teuma@hotmail.fr. 2. UCBL, INSERM, Université de Lyon, Lyon, France. cecile.teuma@hotmail.fr. 3. Department of Dermatology, Centre Hospitalier Lyon Sud, 69495, Pierre Bénite, France. 4. Centre de Recherche en Cancérologie de Lyon, Lyon, France. 5. Department of Nephrology, Centre Hospitalier Lyon Sud, 165, Chemin du Grand Revoyet, 69495, Pierre Bénite, France. 6. UCBL, INSERM, Université de Lyon, Lyon, France.
Abstract
PURPOSE: Vemurafenib (VMF) is a B-RAF inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the incidence and severity of AKI, we conducted a retrospective, observational, monocentric study in the Lyon Sud Hospital University, France, which included 74 patients with metastatic B-RAF-mutated melanomas treated with VMF, between June 2011 and August 2014. According to the Kidney Disease Improving Global Outcomes Guidelines, AKI is defined as an increase in serum creatinine concentration exceeding the baseline concentration by 1.5 fold. Serum creatinine was thus determined before treatment, on a monthly basis during treatment, and 3 months after treatment discontinuation. Patients were divided into two main groups: AKI-positive (AKI+) and AKI-negative (AKI-) and further subdivided into three groups according to AKI severity (stage 1, 2 or 3). To visualize the tissue damage caused by VMF, kidney biopsies were performed for two stage 1 AKI+ patients. RESULTS: Of the 74 patients, 30 (40.5 %) were AKI-, and of the 44 AKI+ patients (59.5 %), 29 (66 %) were diagnosed within the first three months of treatment. There were significantly more men in the AKI+ group: n = 33 (75 %) versus n = 12 (40 %) women, p = 0.004 with an odds ratio for developing AKI of 4.6 (95 % CI 1.48-14.23). Most AKI + cases were considered as stage 1 (n = 40; 91 %) and the remaining four (9 %) as stage 2 AKI. Kidney biopsies revealed interstitial fibrosis and acute focal tubular damage. However, renal failure was reversible in 80 % of patients within 3 months of VMF discontinuation. CONCLUSIONS: We observed frequent, reversible, moderately severe AKI with some histological evidence of tubular and interstitial damage in VMF-treated patients, suggesting that renal function should be carefully monitored in male patients, especially during the first 3 months.
PURPOSE:Vemurafenib (VMF) is a B-RAF inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the incidence and severity of AKI, we conducted a retrospective, observational, monocentric study in the Lyon Sud Hospital University, France, which included 74 patients with metastatic B-RAF-mutated melanomas treated with VMF, between June 2011 and August 2014. According to the Kidney Disease Improving Global Outcomes Guidelines, AKI is defined as an increase in serum creatinine concentration exceeding the baseline concentration by 1.5 fold. Serum creatinine was thus determined before treatment, on a monthly basis during treatment, and 3 months after treatment discontinuation. Patients were divided into two main groups: AKI-positive (AKI+) and AKI-negative (AKI-) and further subdivided into three groups according to AKI severity (stage 1, 2 or 3). To visualize the tissue damage caused by VMF, kidney biopsies were performed for two stage 1 AKI+ patients. RESULTS: Of the 74 patients, 30 (40.5 %) were AKI-, and of the 44 AKI+ patients (59.5 %), 29 (66 %) were diagnosed within the first three months of treatment. There were significantly more men in the AKI+ group: n = 33 (75 %) versus n = 12 (40 %) women, p = 0.004 with an odds ratio for developing AKI of 4.6 (95 % CI 1.48-14.23). Most AKI + cases were considered as stage 1 (n = 40; 91 %) and the remaining four (9 %) as stage 2 AKI. Kidney biopsies revealed interstitial fibrosis and acute focal tubular damage. However, renal failure was reversible in 80 % of patients within 3 months of VMF discontinuation. CONCLUSIONS: We observed frequent, reversible, moderately severe AKI with some histological evidence of tubular and interstitial damage in VMF-treated patients, suggesting that renal function should be carefully monitored in male patients, especially during the first 3 months.
Authors: Yuntao Bai; Ji Young Kim; Bijay Bisunke; Laura A Jayne; Josie A Silvaroli; Michael S Balzer; Megha Gandhi; Kevin M Huang; Veronika Sander; Jason Prosek; Rachel E Cianciolo; Sharyn D Baker; Alex Sparreboom; Kenar D Jhaveri; Katalin Susztak; Amandeep Bajwa; Navjot Singh Pabla Journal: Kidney Int Date: 2021-09-15 Impact factor: 18.998
Authors: Harish Seethapathy; Meghan D Lee; Ian A Strohbehn; Orhan Efe; Nifasha Rusibamayila; Donald F Chute; Robert B Colvin; Ivy A Rosales; Riley M Fadden; Kerry L Reynolds; Ryan J Sullivan; Howard L Kaufman; Kenar D Jhaveri; Meghan E Sise Journal: Nephrol Dial Transplant Date: 2022-02-25 Impact factor: 5.992
Authors: Mehdi Maanaoui; Camille Saint-Jacques; Viviane Gnemmi; Marie Frimat; Arnaud Lionet; Marc Hazzan; Christian Noël; François Provot Journal: Medicine (Baltimore) Date: 2017-06 Impact factor: 1.889
Authors: Lucie Heinzerling; Thomas K Eigentler; Michael Fluck; Jessica C Hassel; Daniela Heller-Schenck; Jan Leipe; Matthias Pauschinger; Arndt Vogel; Lisa Zimmer; Ralf Gutzmer Journal: ESMO Open Date: 2019-05-23
Authors: Muhammad Erfan Uddin; Eric D Eisenmann; Yang Li; Kevin M Huang; Dominique A Garrison; Zahra Talebi; Alice A Gibson; Yan Jin; Mahesh Nepal; Ingrid M Bonilla; Qiang Fu; Xinxin Sun; Alec Millar; Mikhail Tarasov; Christopher E Jay; Xiaoming Cui; Heidi J Einolf; Ryan M Pelis; Sakima A Smith; Przemysław B Radwański; Douglas H Sweet; Jörg König; Martin F Fromm; Cynthia A Carnes; Shuiying Hu; Alex Sparreboom Journal: Int J Mol Sci Date: 2022-08-03 Impact factor: 6.208
Authors: Harish Seethapathy; Halla Bates; Donald F Chute; Ian Strohbehn; Samuel Strohbehn; Riley M Fadden; Kerry L Reynolds; Justine V Cohen; Ryan J Sullivan; Meghan E Sise Journal: Kidney Med Date: 2020-04-18